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Background: Alocasia cucullata (Lour.) G. Don was applied in traditional Chinese medicine for the treatment of
cancer in Chinese Southwest area. Its antitumor effect was scrutinized in vitro and in vivo. And for the first time, the
mechanism of extract of A. cucullata (EAC) against human gastric cancer cell was well examined.
Methods: To detect the most effective fraction, the antiproliferation efficacy of four fractions (namely derivatives by
adding EAC to n-BuOH, petroleum ether, EtOAc and water until dissolve fully) against five cancer cell lines were
screened by MTT assay. Among four fractions, the IC50s of n-BuOH fraction of EAC (EAC-B) against the five cell lines
and time-dependent inhibition to gastric cancer cell line (MGC-803) were further investigated (MTT assay). In vivo
antitumor efficacy of EAC-B was examined by MGC-803 bearing tumor nude mice. Especially, the paper focused on
the relevant mechanism study of EAC-B against MGC-803 included cell cycle distribution (flow cytometry) and cyclin
D1 expression (RT-PCR and western blot), apoptosis (Hoechst 33342 stain and flow cytometry), apoptosis-related
protein expression (Akt, p-Akt, ERK, p-ERK, Bcl-2, Bax) by western blot, and caspase3/7 activity assay.
Results: EAC-B showed its cytotoxicity against various tumor cell lines, particularly against gastric cancer cells with
IC50 value of 18.8 μg/mL in vitro. Tumor weight was significantly reduced by EAC-B in vivo. In the mechanism study,
EAC-B increased cell ratio at G0/G1 phase and reduced cyclin D1 expression both at protein and mRNA level on
MGC-803. Chromatin condensation and apoptosis were also observed. EAC-B down-regulated p-Akt, p-ERK
expression and up-regulated Bax/Bcl-2 ratio. Further, caspase 3/7 activation was enhanced as well.
Conclusions: This study demonstrated that EAC-B had potent antitumor activity both in vitro and in vivo. Its
mechanism is primarily via antiproliferation of G0/G1 arrest and cell pro-apoptosis, including PI-3 K/Akt pathway,
ERK activity, stimulated cytochrome C release and caspase 3/7 activity accompanied with an increase of Bax/Bcl-2
ratio. EAC-B may be a potential source of novel compounds for gastric cancer treatment.
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Cancer as a world-wide concern remains major threat to
people health despite advances in modern medical diagno-
sis and treatment [1]. Gastric cancer (GC) is the fourth
most common malignancy and the second most dangerous
cause of cancer mortality. According to statistics in the
magazine as GLOBOCAN 2008 [2], 989,600 new GC cases* Correspondence: zhengxwsh@hotmail.com
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unless otherwise stated.were recorded and 738,000 deaths occurred. GC is usually
treated with adjuvant chemotherapy prior to and after sur-
gery to prevent cancer recurrence. A meta-analysis demon-
strated that 5-year overall survival increased by 6% with
chemotherapy compared to surgical treatment alone [3]. A
significant and continuous need for effective anticancer
agents was called for. Fortunately, Paclitaxel (Taxol) is
proved to be a successful drug extracted from natural prod-
uct to answer the call to fill the need. The significance of
healing property herbs has been highly evaluated in drug
discovery. However, only 15% and 6% of these plants haveis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wei et al. BMC Complementary and Alternative Medicine  (2015) 15:33 Page 2 of 11been screened for phytochemical analysis and bioactivity,
respectively [4].
Accumulated studies have shown that Chinese traditional
herbs may reduce the side effects, prolong survival time and
improve the quality of life [5]. A review showed that GC
was top 3 of the reported cancers treated with traditional
Chinese medicine in China [6]. For instance, “Huachansu”
has shown significant effects on the improvement of
leukopenia, adverse events and rate of short-term remission
in the advanced or late GC patients [7].
Alocasia cucullata (Lour.) G. Don (Chinese taro) (AC)
in the Araceae family is a fast growing and propagating
herbaceous species prevalent in South China [8]. Its tuber
(Chinese name “jianweiyu”) is a well-known ethnic medi-
cine of the Zhuang nationality in China and is usually ap-
plied to reduce swelling, to detoxify and to ease pain
[9,10]. For centuries in China, the interesting thing is that
it has also been playing role in treatment of cancer in clin-
ical application, including GC [11-13]. Pharmacological
studies showed that an N-acetyl-D-lactosamine lectin
from AC had the antiproliferation effect against human
SiHa cancer cells [14], and our previous studies also
proved that the 50% ethanol extract of A. cucullata (EAC)
was found to have the most potent antiproliferation effect
on five cancer cells among 50% ethanol, 95% ethanol and
water extracts. EAC petroleum ether extractive fraction
(EAC-PE) also showed weak antiproliferation effect on
MGC-803 and 43 ingredients in this fraction were identi-
fied through GC-MS [15]. Above studies proved the anti-
tumor activity of AC and initiated the pharmacological
research of AC.
In the antitumor mechanism study, AC was reported to
be effective on breast cancer [16] while A. macrorrhiza
was reported on the hepatic cancer [17]. It was the first
time for GC that the antitumor effect of EAC in vitro and
in vivo were further evaluated and the possible mecha-
nisms was elucidated by us.
In the study, the antiproliferation effect of four EAC
fractions including n-BuOH fraction against five cancer
cell lines was screened. HPLC demonstrated the phyto-
chemistry difference between n-BuOH and petroleum
ether fractions. Further, the inhibition to tumor growth
in vivo was evaluated with the n-BuOH fraction of EAC
(EAC-B). We also investigated the mechanisms why EAC-




The tubers of AC were collected in Sichuan Province, China
in spring, and were authenticated by Professor Baokang
Huang (the School of Pharmacy, Second Military Medical
University, Shanghai, China). A voucher specimen (Zheng
5470) has been deposited in the Department of ChineseMateria Medica, Shanghai University of Traditional Chinese
Medicine.Extraction and isolation
The 50% ethanol extraction of AC was found to show stron-
ger inhibition effect on five human tumor cells than 95%
ethanol and water extraction [15]. And the extraction was
processed as described previously. The fresh tubers of AC
(90 kg) were washed, sliced, dried in the sun and then ex-
tracted with 50% ethanol three times (1:8, 1:6 and 1:6, w:v),
and the extract was evaporated in vacuo to yield a residue
(400 g). The residue was suspended in water, and then parti-
tioned with petroleum ether, EtOAc and n-BuOH ordinally.
The three fractions and residual of water fraction were evap-
orated in vacuo. The weights of the four fractions were 9 g,
170 g, 65 g and 152 g, respectively.Sample preparation
For HPLC analysis, 50 mg samples each were dissolved in
MeOH with 1 mg/mL. The solutions were then filtered
through 0.2 μm filters (Millipore Co., Bedford, MA, USA).
For bioassays, 30 mg samples each were dissolved with
DMSO or 70% ethanol into 30 mg/mL. And the solutions
were diluted into 50 μg/mL of top dose, then with 2 fold
of serial dilution. Solution stocks were stored at -20°C be-
fore use.Cell culture
The human cell lines, MGC-803 (gastric cancer cells), Hela
(cervical cancer cells), Bel7402 (liver cancer cells), K-562
(myelogenous leukemia cells), MDA-MB-435 (breast can-
cer cells) were obtained from the Cell Resource Center, the
Shanghai Institute of Life Sciences (Shanghai, China). All
cells were cultured in DMEM (Hyclone) with 10% fetal bo-
vine serum (Life Technology) and 1% penicillin–strepto-
mycin in an atmosphere of 5% CO2 at 37°C.HPLC analysis
The HPLC analysis was carried out on an Agilent 1200
HPLC system (Agilent Techonologies, Santa Clara, CA,
USA), combined with Prodigy ODS (2) column of 250 ×
4.6 mm i.d., 5 μ (Phenomenex, Torrance,CA, USA), and
guard column of 7.5 × 3.2 mm i.d.. Gradient elution was
applied, using MeOH (solvent A) and water (solvent B) as
mobile phase components. The flow rate was 1.0 mL/min
at 25°C and injection volume was 20 μL. Gradient elution
started with 5% solvent A and 95% solvent B. The elution
was changed to 10% A and 90% B at 10 min, then to 50%
A and 50% B at 15 min, and ended with 80% A and 20% B
at 70 min. The detection wavelength was set to 205 nm
(range of 196 - 450 nm).
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The in vitro antiproliferation efficacy of four fractions from
EAC on the five cancer cell lines was investigated by MTT
assay [18]. Briefly, cells were plated in 96-well plate (2000
cells/well). After plating overnight, cells were starved with-
out serum for 24 h before treatment with 50 μg/mL of sam-
ples for 24 h. 10 μL of 0.5 mg/mL MTT was added to each
well. Then read the absorbance at 492 nm. Experiments
were conducted in triplicates. With the procedure above,
IC50 were tested by 48 h treatment with various concentra-
tion of EAC-B. Additionally, EAC-B IC50s of 24 h, 48 h and
72 h treatment on MGC-803 were tested.
In vivo antitumor efficacy of EAC-B on MGC-803 tumor
bearing nude mice
Animal welfare and experimental procedures were in
accordance with institutional guidelines for the care and
use of laboratory animals and the related ethical regula-
tions of Shanghai University of Traditional Chinese
Medicine. BALB/c nude mice were subcutaneously
injected at the right armpit with MGC-803 cells (2 ×
106/0.2 mL). All mice were sexually divided into five
groups randomly: negative control (PBS), CTX control
(cyclophosphamide) and three testing groups, with five
mice per group. The mice in CTX control group were
peritoneally injected CTX (0.05 g/kg) once a day, and
the mice in drug/PBS groups were infused EAC-B intra-
gastrically. The body weight was measured every day.
On the 21st, the mice were killed and tumors were iso-
lated and weighed.
Hematoxylin and eosin (HE) staining
Ten % formalin-fixed tumor samples were dehydrated, em-
bedded in the paraffin and sectioned into 4 μM slices. The
slices were visualized with HE staining.
Hoechst 33342 stain
MGC-803 cells were plated in 96-well plate (2000 cells/well).
After plating for 24 h, cells were incubated with 50 μg/mL
of EAC-B for duration of 0, 2, 8 h, then washed with PBS
for twice prior to Hoechst 33342 (10 μg/mL) addition, and
then incubated in dark for 20 min. The morphologic change
was observed with the fluorescent microscope.
Cell cycle analysis by flow cytometry
MGC-803 cells were plated in 6-well plates (1 × 105 cells/
well). After 24 h plating and then 24 h serum starvation,
cells were incubated with the EAC-B for 4 h with various
doses, then harvested by trypsinization, fixed with cold 70%
ethanol at 4°C for 30 min and washed with PBS twice. The
cell pellet was incubated in a solution containing 50 μg/mL
propidium iodide (PI), 0.2 mg/mL RNase, and 0.1% Triton
X-100 at room temperature in dark for 30 min. The cells
were analyzed by flow cytometer (BD, FACSCalibur).Cell apoptosis analysis by flow cytometry
In brief, we treated MGC-803 cells with various doses of
EAC-B for 4 h. Then cells were harvested, washed and
incubated with the solution of Annexin V-FITC for
20 min and then PI (50 μg/mL) for 10 min. All staining
operations must be carried out on ice and in dark. The
cells were analyzed by flow cytometer.
Reverse transcriptase polymerase chain reaction (RT-PCR)
MGC-803 cells were harvested after treated with 31 μg/mL
of EAC-B for 4 h. Total RNA was extracted using Trizol re-
agent (Gibco). Equal amount (1 μg) of total RNA samples
were reverse transcribed into cDNA using reverse tran-
scription kit (Gibco) and amplified. The primer sequences
are as follows [19]. Cyclin D1, forward: 5′-CGT CCA TGC
GGA AGATC-3′, reverse: 5′-CAG AGG GCA ACG AAG
GT-3′ (406 bp); GAPDH, forward: 5′-CGG AGT CAA
CGG ATT TGG TCG TAT-3′, reverse: 5′-AGC CTT CTC
CAT GGT GGT GAA GAC-3′ (306 bp). PCR was per-
formed as follows: denaturation at 94°C for 3 min, 40 cycles
of 94°C for 30 s, 57°C for 30 s and 72°C for 2 min, followed
by a final extension at 72°C for 10 min. Expression of the
genes was analyzed by gel imaging system.
Western blot assay
MGC-803 cells were treated with various concentration of
EAC-B for 24 h. Cell lysates were prepared in a buffer con-
taining 0.2% (w/v) SDS, 0.5% (v/v) Triton X-100, 0.5% (w/v)
sodium deoxycholate, 1 mM PMSF, and 1% protease inhibi-
tor cocktail. The total protein content was measured by
BAC protein assay. The equal amount of protein was elec-
trophoresed on 10% SDS-PAGE and transferred to PVDF
membranes. The membranes were blocked, incubated over-
night with primary antibodies at 4°C, and subsequently in-
cubated with secondary horseradish peroxidase-conjugated
goat anti-rabbit or goat anti-mouse IgG (Abcam). The
following antibodies were used: Akt and p-Akt from Cell
Signaling, cyclinD1, ERK, p-ERK, Bcl-2, Bax, GAPDH and
β-actin from Santa Cruz. The blots were visualized using
ECL detection reagents (Pierce).
Caspase3/7 activity assay
MGC-803 cells were plated in 96-well plate (4000 cells/well).
After 24 h, cells were treated with 0 to 50 μg/mL of EAC-B
or culture medium (1% DMSO) for 5 h, then added the
equal volume reagent of Caspase3/7 (Promega), followed
with standing for 30 min. The contents of Caspase3/7 were
quantified and reflected apoptosis by luminescence with mi-
croplate reader.
Statistical analysis
Statistical software SPSS15.0 was used for statistical analysis.
Data were expressed as mean ± SD. Difference between in-
dependent groups was analysed using the Student’s t-test.
Figure 1 HPLC-UV profiles of fractions partitioned from the EAC. (A) EAC-B; (B) EAC-PE. (UV λ = 205 nm).
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HPLC profile
To distinguish and deepen our previous study [13,15],
the HPLC chromatograms demonstrated the phyto-
chemistry difference between EAC-B and EAC-PE. As
shown in Figure 1, we detected five major peaks in
EAC-B HPLC chromatograms, while eleven major peaks
were confirmed in EAC-PE. The retention times were
also different (EAC-B: 1.2, 2.5, 18.6, 21.9, 23.9 min;
EAC-PE: 1.5, 20.2, 36.1, 37.2, 41.3, 43.1, 46.2, 49.3, 56.2,
57.5, 61.8 min). The HPLC chromatograms demon-
strated the phytochemistry difference between EAC-B
and EAC-PE.Table 1 Inhibition effect of different fraction of EAC on 5 can
Origin Single dose (50 μg/mL)
EAC-PE EAC-
Gastric carcinoma (MGC-803) 21.3 ± 1.3 87.0 ±
Breast carcinoma (MDA-MB-435) 19.9 ± 3.9 76.0 ±
Myelogenous leukemia carcinoma (K-562) 30.3 ± 0.3 73.9 ±
Liver carcinoma (Bel7402) 18.3 ± 1.1 65.9 ±
Cervical carcinoma (Hela) 11.6 ± 4.9 19.3 ±
*EAC-E: the EtOAc fraction of EAC; **EAC-W: the water fraction of EAC.Antiproliferation activity of EAC-B in human cell lines
Four fractions of EAC were prepared and their growth
inhibition activity at high concentration was identified
using MTT assay against a panel of human cancer
cell lines (Table 1). EAC-B showed more than 50%
antiproliferative activity against four cell lines at 50 μg/mL
except Hela cell. The EAC-B presented the antiprolifera-
tion on four cancer cell lines dose-dependently with 48 h
treatment. MGC-803 showed the highest susceptibility to
the EAC-B with the IC50 value of 24.1 μg/mL. Further-
more, EAC-B showed inhibition effect on gastric carcin-
oma in time-dependent manner (Figure 2) with the most
potent IC50 (18.8 μg/mL) after 72 h treatment.cer cell lines
inhibition at 24 h (%) IC50 of EAC-B
at 48 h (μg/mL)B EAC-E* EAC-W**
6.2 16.0 ± 2.0 12.1 ± 1.7 24.1 ± 3.7
0.4 15.4 ± 3.7 10.2 ± 3.0 26.0 ± 2.7
0.3 22.5 ± 3.8 17.3 ± 3.6 27.9 ± 7.8
5.1 15.8 ± 3.6 3.6 ± 3.1 39.9 ± 6.1
1.3 13.5 ± 0.7 2.6 ± 1.5 >50
Figure 2 Cytotoxic effect of EAC-B on MGC-803 in time-dependent
manner by MTT assay. MGC-803 was treated with various doses of
EAC-B for 24, 48, or 72 h. n= 3, mean± SD.
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treated mice
EAC-B inhibited the tumor growth in a dose-dependent
manner (Figure 3). 1 g/kg and 5 g/kg were effective
dose with approximately 50-90% of antitumor activity.
Extract treatment had better role in female mice than
in male mice, especially in high dose treatment (1 g/kgA
B
PBS
Figure 3 Inhibited effect of EAC-B to tumor growth in vivo. (A) BALB/c
injection of MGC-803 cells (2 × 106/mouse) followed by treatment. The trea
injection), EAC-B of 0.2, 1 and 5 g/kg (intragastric infusion). The scatter diag
Significant difference were labelled with asterisk (p < 0.05) compared to PB
(×20 of magnification). The loss of tumor cells (arrows) indicated necrosis (and 5 g/kg). Although 5 g/kg was quite a high dose in
our experiment, 5 g/kg didn’t present significant difference
to 1 g/kg to the antitumor effect. Furthermore, all mice,
including of mice of 5 g/kg groups, were alive until
sacrifice, perhaps suggesting that the low toxicity of
EAC-B. In treated mice, loss of quite amount of cells
(arrows) indicated areas of necrosis by EAC-B.Changes of cell cycle detected by flow cytometric analysis
As shown in Figure 4A and B, the cell cycle of
MGC-803 cells was changed obviously. Compared to
the EAC-B free group, as early as 4 h, the number of
cells in the G0/G1 phase was significantly increased in
a dose-dependent manner. Cell amount in the S and
G2 phase did not present any trend. The progression
of cell cycle was arrested at G0/G1 phase.Effects of EAC-B on the mRNA and protein expression of
cell cycle protein (Cyclin D1)
It was identified early on 4 h that EAC-B reduced the
mRNA level of cyclin D1 (p < 0.001). Similarly, cyclin D1
protein level, detected by western blotting, was down-
regulated (p < 0.001) (Figure 5).EAC-B
nude mice were sacrificed at the 21st days after subcutaneous
tment included of PBS (control), CTX (cyclophosphamide, peritoneal
rams represented the tumor weight of each female and male animal.
S groups. (B) Histological change of the tumor tissue by HE staining
right).
Figure 4 EAC-B induced G0/G1 arrest in MGC-803 cells. (A) Flow cytometry assay for the cell cycles of EAC-B treated MGC-803. Cells were
treated with various doses of EAC-B for 4 h and then trypsinized, fixed, and stained with PI to measure cell cycle by flow cytometry. (B) bar graph
summarized percentage of cells in every cycle. n = 3, mean ± SD. a: pp < 0.05, b: p < 0.01, vs. 0 μg/mL group.
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In a pilot assay of Hoechst 33342, a rapid assay based on
fluorescent detection of compacted chromatin in apop-
totic cells, MGC-803 cells were incubated with 50 μg/mL
of EAC-B by 0, 2, 8 h. After 2 h incubation, MGC-803
cells began to apoptosis. After 8 h, some cells died
(Figure 6).
Flow cytometric analysis of cell apoptosis
Flow cytometry was used to identify and quantify the
apoptosis and necrosis cells. MGC-803 cells were treatedwith EAC-B of 0, 10, 20, 30, 40 and 50 μg/mL. Then cells
were stained with Annexin V-FITC/PI and subsequently
analysed by flow cytometry. The four quadrants of the
dual parameter fluorescent dot plots represented different
states of the cells. The viable cells population was in the
lower left quadrant (Annexin V−/PI−). The early apoptotic
cells were in the lower right quadrant (Annexin V+/PI−)
and the ones in late apoptosis were in the upper right
quadrant (Annexin V+/PI+). As shown in Figure 7A and
B, as early as 4 h, with the increasing concentration of the
EAC-B, the proportion of apoptotic cells increased.
A B
Figure 5 EAC-B downregulated cell cycle related gene/protein (Cyclin D1) expression. MGC-803 cells were treated with or without 31 μg/mL of
EAC-B for 4 h prior to RT-PCR (A) and western blotting (B) analysis. GADPH was housekeeping control. Left: representative immunoblot; Right: densitomentric
analysis. n= 3, mean± SD. c: p< 0.001, vs. control group.
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cated that the EAC-B may induce apoptosis in MGC-
803 cells.EAC-B inhibited Akt and ERK in MGC-803 cells
The biochemical mechanism by which EAC-B caused
cells to enter apoptosis was explored with the PI-3 K
and MAPK signaling pathway. The expression of p-Akt,
Akt, p-ERK and ERK after drug treatment were mea-
sured by western blotting (Figure 8A and B). EAC-B
reduced both expression of p-Akt and p-ERK by dose-
dependent manner, but no effect on Akt and ERK. This
means EAC-B may affect the PI-3 K and MAPK pathway
in cell apoptosis.EAC-B increased Bax/Bcl-2 ratio in MGC-803 cells
To further investigate the effect of EAC-B on apoptosis-
regulatory proteins, we also examined the expression of
anti-apoptosis molecule Bcl-2 and pro-apoptosis mol-
ecule Bax in MGC-803 cells. As shown in Figure 8C and
D, EAC-B significantly decreased the expression of Bcl-2
and increased the expression of Bax in a dose-dependentFigure 6 Hoechst 33342 staining exhibited that EAC-B induced chrom
independent experiments are shown.manner, which caused an increased ratio of Bax to Bcl-2
(Figure 8E).
EAC-B extract activated Caspase3/7
Since one possible apoptotic pathway has been thought
that cytochrome C released from mitochondria could
trigger the caspase cascade [19], we evaluated the Cas-
pase3/7 activity in MGC-803 cells with treatment of
EAC-B. As shown in Figure 9. Caspase3/7 activity, mea-
sured by using a luminescent caspase activity assay kit,
increased proportionately with EAC-B concentration of
treatment in MGC-803 cells.
Discussion
AC has been applied for treating cancer patients in trad-
itional Chinese medicine. The antitumor effect of EAC
was reported in our previous study [15], and 50% etha-
nol extract showed the strongest inhibition to cancer cell
lines. In this paper, we further partitioned the 50% etha-
nol extract and investigated the antitumor effect and
mechanism of EAC for the first time. The four extractive
fractions were screened in terms of antiproliferation
in vitro against various cancer cell lines. EAC-B showedatin shrinking of MGC-803 cells. Representative pictures of 3
Figure 7 Flow cytometric analysis of MGC-803 cells apoptosis induced by EAC-B. MGC-803 cells were treated with different concentration
of EAC-B for 4 h, and then harvested, stained with Annexin V-FITC and propidium iodide (PI). (A) MGC-803 cytogram from flow cytometric
analysis. MGC-803 cells were treated with EAC-B at 0 (control), 10, 20, 30, 40 and 50 μg/mL. (B) Percentage of Annexin V positive cells.
n = 3, mean ± SD.
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cancer cell line of MGC-803 with IC50 value of 18.8 μg/
mL, while traditionally, AC was used in folk medicine
for GC. To distinguish the component difference be-
tween EAC-B and EAC-PE [13], we demonstrated the
phytochemistry by HPLC. Herein, EAC-B was scruti-
nized the potential and mechanism against GC in vitro
and in vivo.
In vivo, EAC-B exerted stronger tumor inhibition on
female mice than male mice, especially with high dose
treatment. The gender susceptibility on GC is in accord-
ance with the AC clinical application on breast cancer.
Furthermore, compared with the highest dose (0.8 g/kg)
in Fang’s report [16], we treated the model mice with
higher dose treatment up to 5 g/kg. It was interesting
that the mice were all alive when sacrifice, which was
speculated the low toxicity of EAC-B in animal models.
Depending on the disabled cell cycle regulation, un-
controlled cell proliferation is the hallmark of cancer
[20]. In cell culture, cell cycle arrest sufficient to cell
senescence is a common barrier to cancer [21]. Cyclins
are well-studied cell cycle regulators. Cyclin D1 is par-
ticularly required at G1 to S phase. Cyclin D1, together
with its cell dependent kinase 4/6 partner, is responsible
for the transition to S phase by retinoblastoma protein
(Rb) phosphorylation [22]. Over-expression of Cyclin D1
oncogene can release cell from their normal cell cycle
control and causes transformation to neoplasia [22].
Novel antitumor agent may derive from Cyclin D1 in-
hibition [23]. In our study, EAC-B inhibited the cell pro-
liferation via G0/G1 cell cycle arrest, accompanied witha decrease of Cyclin D1 both on protein and mRNA
level. Therefore, our results suggested that EAC-B sup-
pressed MGC-803 proliferation by affecting cell cycle ar-
rest and inhibiting Cyclin D1.
In this study, nucleus shrinking, one of morphologic
alterations of apoptosis [24] was detected by Hoechst
staining. Apoptotic cells ratio was increased in a dose-
dependent manner by EAC-B by flow cytometry. These
suggested that the mechanism of tumor inhibition by
EAC-B was associated with cell apoptosis. MTT is an
index of mitochondrial viability because it is reduced by
metabolically active mitochondria [25]. Our results indi-
cated that EAC-B exerted a decrease in MGC-803 cells
mitochondrial viability with IC50 value of 18.8 μg/mL.
The result suggested that the apoptosis pathway may be
controlled by mitochondrion. The PI-3 K/Akt pathway is
a significant anti-apoptotic/survival signaling pathway in
cancer cells. Its role in the regulation of mitochondrial
functions has drawn more attentions [26]. Akt, a proto-
oncogene, is a key protein in this pathway. The phos-
phorylation of Akt leads to its activation [24]. Bcl-2 and
Bax, the anti-apoptosis protein and pro-apoptosis pro-
tein, act as the downstream regulators of Akt and acti-
vated Akt, following with regulating mitochondrial
outer membrane permeabilization that favors the release
different apoptogenic factors, such as cytochrome C
[27,28], and hence to trigger apoptotic caspase activation,
including caspase 3/7. Activated Akt phosphorylates BAD,
dissociates BAD from Bcl-2 or Bcl-xL and thus suppresses
apoptosis [29]. Phosphorylation of Bax by Akt or activated




Figure 8 Western blotting analysis of apoptosis regulatory proteins in MGC-803 cells after treatment with increasing concentration of
EAC-B for 24 h. Densitometry was performed for the different protein and normalized to the respective housekeeping control (A-D). Bax/Bcl-2
ratio from the densitometric analysis (E). n = 3, mean ± SD.
Figure 9 Caspase3/7 activity in MGC-803 cells treated with 0,
10, 20, 30, 40 and 50 μg/mL of EAC-B. The increasing caspase3/7
activity was reported as Luminescence signal. n = 3, mean ± SD.
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tio of Bax/Bcl-2 determines the susceptibility of MGC-803
to apoptosis [30,31]. In this study, p-AKT was significantly
decreased by EAC-B in a dose-dependent manner, while
EAC-B treatment didn’t change AKT expression. We
also found that the expression of Bcl-2 protein de-
creased and the expression of Bax protein increased
which led to an increase of the Bax/Bcl-2 ratio. The
present results showed that EAC-B exhibited antitumor
by stimulating apoptosis.
A growing number of studies have confirmed the im-
plantation of the Ras/Raf/ERK signaling pathway in the
induction of cell apoptosis in vitro and in vivo [32]. ERK
activity could also promote cytochrome C release by
modulating Bcl-2 family protein expression. Furthermore,
MEK/ERK activity has been associated with the upregula-
tion of pro-apoptotic members of the Bcl-2 family, and
the downregulation of anti-apoptotic members, such as
Bcl-2 and Bcl-xL.
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by inhibition of p-Akt and p-ERK, following with involve-
ment of Bcl-2, Bax, and cytochrome C release and apoptosis
execution by caspase3/7.
Conclusions
In summary, our results showed that EAC-B significantly
inhibited cancer cells growth in vitro and in vivo. The mo-
lecular mechanisms may involve 1) PI-3 K/Akt pathway of
apoptosis; 2) ERK activity of apoptosis; 3) triggering of mito-
chondrial pathway; 4) connection by Bcl-2 and Bax; 5) G0/
G1 cell cycle arrest. It is clinically confirmed that Alocasia is
effective for cancer treatment proved by modern Chinese
medicine and folk medicine, especially for GC and breast
cancer. The research of Alocasia is not systematic despite ef-
forts people devote to. Our study for BuOH fraction of ex-
tract from A. cucullata (one species of Alocasia), may
discover that EAC-B might be used as a potential agent for
treating GC.
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